[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:metastatic-castration-sensitive-prostate-cancer":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":15,"states":16},"Metastatic Castration Sensitive Prostate Cancer",1,[7],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07028853","This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.",[11],"Phase 3","RECRUITING","2026-08-26T02:18:46.137046Z","2026-07-05T05:32:16.729396Z",[],[]]